Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 14/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.42 |
| ▸ | FLT4 | P35916 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | FER | P16591 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.42 |
| ▸ | STK3 | Q13188 | 1/20 | 0.42 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.42 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162849 | 0.89 | CHEK1 (0.42) | CHEK1RPS6KA3FLT4FLT3SRPK1 | |
| SCHEMBL12643242 | 0.89 | KDM4E (0.47) | CHEK1RPS6KA3FLT4FLT3SRPK1 | |
| SCHEMBL2037624 | 0.89 | KDM4E (0.47) | CHEK1RPS6KA3FLT4FLT3SRPK1 | |
| SCHEMBL13677587 | 0.89 | KDM4E (0.47) | CHEK1RPS6KA3FLT4FLT3SRPK1 | |
| SCHEMBL2031893 | 0.87 | CHEK1 (0.49) | CHEK1HRH3FECHKCNH2CDK5 | |
| SCHEMBL5164315 | 0.85 | IDH2 (0.46) | CHEK1HRH3FECHKCNH2 | |
| SCHEMBL27644594 | 0.85 | CHEK1 (0.44) | CHEK1RPS6KA3FLT4FLT3SRPK1 | |
| SCHEMBL2036333 | 0.83 | KDM4E (0.51) | CHEK1RPS6KA3FLT4FLT3SRPK1 | |
| SCHEMBL5163171 | 0.82 | CHEK1 (0.44) | CHEK1RPS6KA3FLT4FLT3SRPK1 | |
| SCHEMBL2037001 | 0.82 | CHEK1 (0.54) | CHEK1FECHKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101006075-A | Bisarylurea derivatives useful for inhibiting CHK1 | ICOS CORP (US) | 2007-07-25 | — | — | CN | claimed |
| EP-1765808-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS Corporation (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006012308-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-02 | — | — | WO | claimed |
| US-20070185013-A1 | Use of chk1 inhibitors to control cell proliferation | ICOS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| CN-101006075-A | Bisarylurea derivatives useful for inhibiting CHK1 | ICOS CORP (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1765808-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006012308-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185013-A1 | Use of chk1 inhibitors to control cell proliferation | CHEK1, CHEK2, CDC25C | CHEK1 1/4885RPS6KA3 1084/4885FLT4 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.